Abstract:Butyrylcholinesterase (BChE) has been considered as a potential therapeutic target for Alzheimer's disease (AD) because of its compensation capacity to hydrolyze acetylcholine (ACh) and its close association with Aβ deposit. Here, we identified S06-1011 (hBChE IC50 = 16 nM) and S06-1031 (hBChE IC50 = 25 nM) as highly effective and selective BChE inhibitors, which were proved to be safe and long-acting. Candidate compounds exhibited neuroprotective effects and the ability to improve cognition in scopolamine- and Aβ1–42 peptide-induced cognitive deficit models. The best candidate S06-1011 increased the level of ghrelin, a substrate of BChE, which can function as improving the mental mood appetite. The weight gain of the S06-1011-treated group remarkably increased. Hence, BChE inhibition not only plays a protective role against dementia but also exerts a great effect on treating and nursing care.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00167?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00167</a>.Molecular dynamics—8012-9656 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_001.pdb">PDB</a>)Molecular dynamics—S06-1002 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_002.pdb">PDB</a>)Molecular dynamics—S06-1011 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_003.pdb">PDB</a>)Molecular dynamics—S06-1014 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_004.pdb">PDB</a>)Molecular string formulas (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_005.csv">CSV</a>)Compound characterization; inhibitory rates on eeAChE and on eqBChE of partial compounds; molecular docking modes of S06-1002, S06-1011, and S06-1014; molecular dynamic simulation results of S06-1001, S06-1002, S06-1011, and S06-1014; chromatographic and mass spectrometric identification information for S06-1011; standard curves for pharmacokinetics and PAMPA study; quantization of ROS production; protocol for the in vivo experiments (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_006.pdf">PDF</a>)This article has not yet been cited by other publications.

Discovery of Selective Butyrylcholinesterase (BChE) Inhibitors through a Combination of Computational Studies and Biological Evaluations.

Discovery, Structure-Based Modification, In Vitro , In Vivo , and In Silico Exploration of m -Sulfamoyl Benzoamide Derivatives as Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer’s Disease

Expansion of the Scaffold Diversity for the Development of Highly Selective Butyrylcholinesterase (bche) Inhibitors: Discovery of New Hits Through the Pharmacophore Model Generation, Virtual Screening and Molecular Dynamics Simulation.

Discovery, Structure-Based Modification, in Vitro, in Vivo, and in Silico Exploration of M-Sulfamoyl Benzoamide Derivatives As Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer's Disease.

Discovery of New Selective Butyrylcholinesterase (BChE) Inhibitors with Anti-Aβ Aggregation Activity: Structure-Based Virtual Screening, Hit Optimization and Biological Evaluation

Discovery of a Selective 6-Hydroxy-1, 4-Diazepan-2-one Containing Butyrylcholinesterase Inhibitor by Virtual Screening and MM-GBSA Rescoring

Synthesis and bio-evaluation of a novel selective butyrylcholinesterase inhibitor discovered through structure-based virtual screening

Discovery, Molecular Dynamic Simulation and Biological Evaluation of Structurally Diverse Cholinesterase Inhibitors with New Scaffold Through Shape-Based Pharmacophore Virtual Screening.

Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease

Synthesis and biological evaluation of substituted acetamide derivatives as potential butyrylcholinestrase inhibitors

Design, Synthesis, Biological Evaluation and Molecular Modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] Dioxole-5-carboxamides As Selective Butyrylcholinesterase Inhibitors.

Recent Progress in the Identification of Selective Butyrylcholinesterase Inhibitors for Alzheimer's Disease.

Design, synthesis and biological evaluation of novel pyrazolone derivatives as selective butyrylcholinesterase inhibitors with antioxidant activity against Alzheimer's disease

Discovery of new multifunctional selective acetylcholinesterase inhibitors: structure-based virtual screening and biological evaluation

Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor

A highly effective and stable butyrylcholinesterase inhibitor with multi-faceted neuroprotection and cognition improvement

Searching for the Multi-Target-Directed Ligands Against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H3R and BACE 1 Inhibitory Activities

Discovery and Biological Evaluation of New Selective Acetylcholinesterase Inhibitors with Anti-Aβ Aggregation Activity Through Molecular Docking-Based Virtual Screening.

Discovery of 4-Benzylpiperazinequinoline BChE Inhibitor That Suppresses Neuroinflammation for the Treatment of Alzheimer's Disease

Contemporary Medicinal-Chemistry Strategies for the Discovery of Selective Butyrylcholinesterase Inhibitors

Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection